New objective endpoints enable better-focused, shorter trials on neuroprotective agents

NICE, France — Advances in optical coherence tomography may help establish new, objective endpoints for clinical trials of neuroprotective agents as glaucoma therapies, according to one specialist. “New-generation OCT technology allows us to visualize the optic nerve where it enters the globe and the Bruch’s membrane finishes. This means we have an objective measure as opposed to subjective evaluation of the edges of the optic disc,” M. Francesca Cordeiro, MD, said at the 2014 European Glaucoma Society meeting.